Concepedia

Mario R. Mautino

MR

31

Publications

1.7K

Citations

20

H-Index

1993

Active since

Affiliations

NewLink Genetics (United States)(Current)

National Institutes of Health

Augusta University

Augusta University Health

Universidad Nacional de Córdoba

Mario R. Mautino is an author at NewLink Genetics (United States) specializing in medicine, immunology, and immunotherapy.

ORCID

Top concepts

Publications per year

1993–2020

31

Publications

31

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

Richard Metz, Sonja Rust, James B. DuHadaway et al. · OncoImmunology · 2012 · 369 citations · Full text

, , +20

The PTEN pathway in T <sub>regs</sub> is a critical driver of the suppressive tumor microenvironment

Madhav Sharma, Rahul Shinde, Tracy L. McGaha et al. · Science Advances · 2015 · 168 citations · Full text

, , +24

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek et al. · Journal for ImmunoTherapy of Cancer · 2018 · 150 citations · Full text

A phase I study of indoximod in patients with advanced malignancies

Hatem Soliman, Susan Minton, Hyo S. Han et al. · Oncotarget · 2016 · 141 citations · Full text

Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.

Mario R. Mautino, Firoz A. Jaipuri, Jesse P. Waldo et al. · Cancer Research · 2013 · 86 citations

, , +24

Rows per page

1–5 of 31